• Home
  • Technologies
  • RNA Detection

RNA Detection

MicroRNAs (miRNAs) and other small RNAs are of increasing interest as potential biomarkers and drug targets. The ability to accurately quantify them from biofluids such as blood, urine, or saliva ("liquid biopsy") is crucial to realizing their potential in early disease detection, diagnosis, drug development, and selecting and following treatment.

SomaGenics has developed NGS library preparation and RealTime qPCR platforms that address important aspects of diagnostic detection of miRNAs and other small RNAs.

RealSeq®-AC- miRNA Sequencing Kit enables the preparation of sequencing libraries for miRNAs or other small RNAs that minimizes bias related to intramolecular RNA folding and adapter dimers. Sequencing costs will be lowered by reducing the number of irrelevant sequencing reads. More about RealSeq®-AC

miR-Direct® allows direct isolation and quantification of circulating miRNAs from biofluids, including Heparin-containing specimens. miR-Direct® enables the detection of low-abundant miRNAs and is an ideal tool for biomarker validation and detection. More about miR-Direct®

miR-ID® is a versatile platform that provides sensitive and highly specific quantification of low abundance small RNAs, such as microRNAs, from total RNA isolates. More about miR-ID®

Platforms under development

miRNA Sequencing

RealSeq® - Biofluids Sequencing Kit is optimized for sequencing miRNAs from biofluids. RealSeq® - Biofluids is based on the RealSeq®-AC core technology, ensuring low bias sequencing libraries.  Please enquire for beta-testing.

RealSeq® - SC Sequencing kit for single cells is a method for miRNA sequencing from single cells.

RealSeq® - T Targeted MicroRNA Sequencing Kit is a method for enrichment and targeted sequencing of selected small RNAs. The use of novel enzymes achieves a high efficiency of adapter ligation to all RNA sequences, thus eliminating ligation bias.

mRNA Analysis

ResQ-RNA enables the detection of fragmented mRNAs. This technology is especially relevant for detection of degraded, cell-free, circulating mRNAs from liquid biopsies, as well as for RNA isolated from FFPE samples.

Contact us for more information on these technologies.

SomaGenics, Inc.
2161 Delaware Avenue
Santa Cruz, CA 95060
U.S.A.
Tel: (831) 426-7700
Fax: (831) 420-0685

General Information

Investor / Business